Zydus PharmaUS-based Zydus Pharmaceuticals, a subsidiary of Zydus Cadila, has received final approval from the US Food and Drug Administration (USFDA) to market Ramipril tablets, in the strengths of 1.25 mg, 2.5 mg, 5 mg and 10 mg.

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor, used to treat hypertension and congestive heart failure.

Cadila Healthcare is the flagship company of the Zydus Cadila group. The group is engaged in pharmaceuticals (human formulations, veterinary formulations and bulk drugs), diagnostics, herbal products, skin care products and OTC products.